CVE-2026-21980 is a medium-severity vulnerability found in the Oracle Life Sciences Central Coding product of Oracle Health Sciences Applications. The affected version is 7.0.1.0. This vulnerability allows unauthenticated attackers with network access via HTTP to compromise the system. Successful exploitation can lead to unauthorized updates, inserts, or deletions of accessible data within Oracle Life Sciences Central Coding, as well as unauthorized read access to a subset of this data.
The vulnerability has a CVSS 3.1 Base Score of 6.5, indicating moderate risk due to its potential impact on confidentiality and integrity. The attack vector is classified as NETWORK, with low complexity and no required privileges or user interaction. Organizations utilizing this product should be aware that the risk to organizations includes unauthorized data manipulation and access.
Current exploitation status indicates that there are no known public exploits or Proof of Concepts (PoCs) available. However, the lack of known exploitation does not diminish the importance of addressing this vulnerability, particularly given its potential impact on sensitive healthcare data.
Organizations should prioritize patching immediately to address this vulnerability and prevent possible unauthorized access or data manipulation.
Vulnerability Details
The CVE description indicates a vulnerability in the Oracle Life Sciences Central Coding product of Oracle Health Sciences Applications. The supported version affected is 7.0.1.0. It is classified as a vulnerability that can be easily exploited by an unauthenticated attacker with network access via HTTP. The successful execution of attacks can allow for unauthorized updates, inserts, or deletions to the accessible data, in addition to unauthorized read access to certain data subsets.
The CVSS score of 6.5 indicates a medium severity level, with confidentiality and integrity impacts. The vulnerability is characterized by a low attack complexity, requiring no privileges or user interaction. The attack vector is classified as NETWORK, emphasizing the need for organizations to address this vulnerability promptly.
Technical Analysis
The root cause of this vulnerability stems from insufficient access controls, allowing an unauthenticated remote attacker to exploit the system. The attack vector is network-based, making it easily accessible for attackers. The complexity of the attack is low, meaning that even those with limited technical skills could potentially exploit this vulnerability.
No special privileges are required for exploitation, and no user interaction is needed, further increasing the risk. The potential impacts on confidentiality and integrity are classified as low, indicating that while data could be accessed or manipulated, it may not necessarily lead to catastrophic failures or loss of availability.
Risk & Impact Analysis
The deployment risk associated with CVE-2026-21980 is significant, particularly for organizations that rely on Oracle Life Sciences Central Coding for managing sensitive health data. The ability for an unauthenticated attacker to gain unauthorized access poses a serious threat to data integrity and confidentiality.
The potential blast radius of this vulnerability could extend to any organization utilizing the affected version, affecting patient data management and compliance with healthcare regulations. Organizations should address this vulnerability in their priority patch cycle to mitigate risks and protect sensitive data.
Exploitation Status
Signal | Status |
|---|---|
Known Exploit | No |
Public PoC | No |
Actively Exploited | No |
Ransomware Use | No |
Affected Versions
The vulnerable version of Oracle Life Sciences Central Coding is 7.0.1.0. Organizations using this version should implement remediation measures as soon as possible.
Mitigation & Remediation
Organizations should prioritize patching to mitigate the risk associated with CVE-2026-21980. The recommended action is to upgrade to the latest version of Oracle Life Sciences Central Coding. If immediate patching is not feasible, organizations should implement network controls to restrict access to this vulnerable component.
Configuration hardening and monitoring systems for unauthorized access attempts can also help in reducing exposure. For further guidance on ensuring security measures are effective, organizations may consider utilizing penetration testing to validate security implementations.
Detection Guidance
Organizations should monitor logs for unauthorized access attempts and unusual behaviors. Detection signatures for network-level attacks targeting Oracle Life Sciences Central Coding should be implemented, and any changes to the system that are not aligned with standard operational procedures should be flagged for review.
AppSecure Threat Intelligence Insight
CVE-2026-21980 highlights the importance of maintaining robust security measures in healthcare applications. As vulnerabilities like this can lead to significant risks, organizations must adopt a proactive approach in managing their security posture.
This incident serves as a reminder to regularly assess and update security configurations, ensuring that systems are resilient against emerging threats. For more insights into vulnerability management best practices, organizations can refer to resources on vulnerability management and penetration testing methodology to enhance their security strategies.
Additionally, organizations are encouraged to stay informed about the latest trends in cybersecurity to better mitigate risks associated with vulnerabilities like CVE-2026-21980.
Disclaimer: This content was generated using AI. While we strive for accuracy, please verify critical information with official sources.
.webp)